Oncology Corporate Profile
Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|tazemetostat||EZH2 inhibitor||Diffuse large B-cell Lymphoma (DLBCL)||II|
|EPZ-6438||EZH2 inhibitor||Non-Hodgkin's Lymphoma (NHL)||II|
|EPZ-5676||DOT1L inhibitor||Acute Myelogenous Leukemia (AML)||I|
View additional information on product candidates here »